Reverse MAPPIT: Screening for protein-protein interaction modifiers in mammalian cells

Nature Methods

Volumn 2, Issue 6, 2005, Pages 427-433

  Eyckerman, Sven ^a,b   Lemmens, Irma ^a   Catteeuw, Dominiek ^a   Verhee, Annick ^a   Vandekerckhove, Joel ^a   Lievens, Sam ^a   Tavernier, Jan ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; ERYTHROPOIETIN RECEPTOR; FK 506 BINDING PROTEIN; GROWTH FACTOR RECEPTOR; POLYPEPTIDE; PROTEIN MDM2; PROTEIN P53; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAMMAL CELL; MONITORING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SCREENING TEST; SIGNAL TRANSDUCTION;

HUMANS; JANUS KINASE 3; PROTEIN INTERACTION MAPPING; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TWO-HYBRID SYSTEM TECHNIQUES;

ANIMALIA; MAMMALIA;

EID: 21444437387     PISSN: 15487091     EISSN: None     Source Type: Journal    
DOI: 10.1038/nmeth760     Document Type: Article

References (37)

1. Zhang, Z.Y., Poorman, R.A., Maggiora, L.L., Heinrikson, R.L. & Kezdy, F.J. Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J. Biol. Chem. 266, 15591-15594 (1991).
2. Moss, N. et al. Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity. J. Med. Chem. 39, 4173-4180 (1996).
3. Adachi, T., Stafford, S., Sur, S. & Alam, R. A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. J. Immunol. 163, 939-946 (1999).
4. L. Nat. Cell Biol. 3, 173-182 (2001).
5. Hayashi, M. et al. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130. Proc. Natl. Acad. Sci. USA 99, 14728-14733 (2002).
6. Hayashi, M. et al. Biological activity of a novel nonpeptide antagonist to the interleukin-6 receptor 20S, 21-epoxy-resibufogenin-3-formate. J. Pharmacol. Exp. Ther. 303, 104-109 (2002).
7. Weitz-Schmidt, G. et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7, 687-692 (2001).
8. Vassilev, L.T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
9. Lepourcelet, M. et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 5, 91-102 (2004).
10. Gadek, T.R. & Nicholas, J.B. Small molecule antagonists of proteins. Biochem. Pharmacol. 65, 1-8 (2003).
11. Bergendahl, V., Heyduk, T. & Burgess, R.R. Luminescence resonance energy transfer-based high-throughput screening assay for inhibitors of essential protein-protein interactions in bacterial RNA polymerase. Appl. Environ. Microbiol. 69, 1492-1498 (2003).
12. Zhao, H.F. et al. A mammalian genetic system to screen for small molecules capable of disrupting protein-protein interactions. Anal. Chem. 76, 2922-2927 (2004).
13. Kato-Stankiewicz, J. et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc. Natl. Acad. Sci. USA 99, 14398-14403 (2002).
14. Huang, J. & Schreiber, S.L. A yeast genetic system for selecting small molecule inhibitors of protein-protein interactions in nanodroplets. Proc. Natl. Acad. Sci. USA 94, 13396-13401 (1997).
15. Vidal, M., Braun, P., Chen, E., Boeke, J.D. & Harlow, E. Genetic characterization of a mammalian protein-protein interaction domain by using a yeast reverse two-hybrid system. Proc. Natl. Acad. Sci. USA 93, 10321-10326 (1996).
16. Park, S.H. & Raines, R.T. Genetic selection for dissociative inhibitors of designated protein-protein interactions. Nat. Biotechnol. 18, 847-851 (2000).
17. Eyckerman, S. et al. Design and application of a cytokine receptor-based interaction trap. Nat. Cell Biol. 3, 1114-1119 (2001).
18. Krebs, D.L. & Hilton, D.J. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19, 378-387 (2001).
19. Yoshimura, A. et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14, 2816-2826 (1995).
20. Baumann, H. et al. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc. Natl. Acad. Sci. USA 93, 8374-8378 (1996).
21. Eyckerman, S., Broekaert, D., Verhee, A., Vandekerckhove, J. & Tavernier, J. Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor. FEBS Lett. 486, 33-37 (2000).
22. Zhang, J.G. et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. USA 96, 2071-2076 (1999).
23. Bjorbaek, C., Elmquist, J.K., Frantz, J.D., Shoelson, S.E. & Flier, J.S. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol. Cell 1, 619-625 (1998).
24. Huse, M., Chen, Y.G., Massague, J. & Kuriyan, J. Crystal structure of the cytoplasmic domain of the type I TGF β receptor in complex with FKBP12. Cell 96, 425-436 (1999).
25. Wang, T., Donahoe, P.K. & Zervos, A.S. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science 265, 674-676 (1994).
26. Cook, W.S. & Unger, R.H. Protein tyrosine phosphatase 1B: a potential leptin resistance factor of obesity. Dev. Cell 2, 385-387 (2002).
27. ten Hoeve, J. et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol. Cell. Biol. 22, 5662-5668 (2002).
28. Chung, C. D. et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 278, 1803-1805 (1997).
29. Chen, Y.G., Liu, F. & Massague, J. Mechanism of TGFbeta receptor inhibition by FKBP12. EMBO J. 16, 3866-3876 (1997).
30. Charng, M.J., Kinnunen, P., Hawker, J., Brand, T. & Schneider, M.D. FKBP-12 recognition is dispensable for signal generation by type I transforming growth factor-βreceptors. J. Biol. Chem. 271, 22941-22944 (1996).
31. Bogan, A.A. & Thorn, K.S. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280, 1-9 (1998).
32. Archakov, A.I. et al. Protein-protein interactions as a target for drugs in proteomics. Proteomics 3, 380-391 (2003).
33. Arkin, M.R. et al. Binding of small molecules to an adaptive protein-protein interface. Proc. Natl. Acad. Sci. USA 100, 1603-1608 (2003).
34. Vidal, M. & Endoh, H. Prospects for drug screening using the reverse two-hybrid system. Trends Biotechnol. 17, 374-381 (1999).
35. Gaber, R.F., Copple, D.M., Kennedy, B.K., Vidal, M. & Bard, M. The yeast gene ERG6 is required for normal membrane function but is not essential for biosynthesis of the cell-cycle-sparking sterol. Mol. Cell. Biol. 9, 3447-3456 (1989).
36. Eyckerman, S. et al. Analysis of Tyr to Phe and fa/fa leptin receptor mutations in the PC12 cell line. Eur. Cytokine Netw. 10, 549-556 (1999).
37. Lemmens, I. et al. Heteromeric MAPPIT: a novel strategy to study modification-dependent protein-protein interactions in mammalian cells. Nucleic Acids Res. 31, e75 (2003).